Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSI-1721 is a recombinant engineered heme-protein based on neuroglobin, currently in preclinical development by Globin Solutions for the treatment of carbon monoxide (CO) poisoning. As a neuroglobin-based CO scavenger, GSI-1721 is designed to bind carbon monoxide with extremely high affinity, effectively sequestering the gas from the bloodstream and tissues. This mechanism aims to reverse the toxic effects of CO poisoning by facilitating the clearance of CO and restoring the oxygen-carrying capacity of endogenous hemoglobin. The protein is engineered to optimize its stability and binding kinetics for therapeutic use as an intravenous antidote.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GSI-1721.